WHY DO WE PRESCRIBE EXPENSIVE NSAIDS FOR JOINT DISEASES AND HEADACHES WHEN THEY speedt cash advance tucson ARE NOT SUPERIOR TO ASPIRIN?
The Lancet (2003;361:573-574) under the title “Effect of ibuprofen on cardioprotective effect of aspirin” documents how NSAIDS interferes with the cardio-protective effect of low dose aspirin. I documented this ten years previously in 1993, in The Ceylon Medical Journal (1993. 38:145-146) under the title “Do NSAIDs interfere with the action of low dose aspirin.
I cite this issue only because I also documented the factual status of aspirin in analgesia and as an anti-inflammatory drug being probably superior to many recent NSAIDs including ibuprofen. ( Mendis, B. L. J. 1995. Joint disease, aspirin and NSAIDs. Kandy Medical Journal, 5: 1-3. Mendis, B. L. J. 1994. short term loans compare Avoiding nightmares in migraine management. Journal of the Ceylon College of Physicians, 27: 54 – 55. Mendis, BLJ. 1996. Aspirin::friend or fiend. Ceylon Medical Journal. 41:76-77.)
Since The Lancet has concluded as I did on the effect of NSAIDs on the action of low dose aspirin, I am hopeful that my colleagues would seriously consider the conclusion of the aforementioned articles, namely, that soluble aspirin is equal or superior for joint disease and headaches compared to the branded preparations that are much prescribed though expensive, have no proven higher therapeutic efficacy and have more side effects.
I am aware that what I am suggesting sounds incredulous but is 1 hr loans based on sound documentation. E.g. soluble aspirin instead of piroxicam. Please take the trouble to read the articles cited in the above references. Should we not be ethically concerned to give the patients a better deal – medically and economically? Drug companies at present do not include aspirin in comparative trials. You are probably aware how a research on COX2 inhibitors was contrived to hide the truth of adverse effects until a journalist on the Washington Post brought it to light. You may read Therapeutic Letter Issue 43 on this.
This letter goes out to a few whom I felt would be concerned.